Physician profile
Thuy Dan DO
NPI 1124336797
$1,619.49
in general payments reported to CMS, 2019-2025
17 companies · $834 in 2025
The $834 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $157 · 2023: $362 · 2024: $267 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $508.30 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $338.95 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Kowa Pharmaceuticals America, INC. | $124.20 | 2024-2025 | Zoryve |
| Glaxosmithkline, LLC. | $92.53 | 2025 | Arexvy |
| Gilead Sciences, INC. | $77.93 | 2022-2025 | |
| Amgen INC. | $68.80 | 2023-2025 | Repatha, Otezla, Repatha |
| Edwards Lifesciences Corporation | $58.14 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $54.87 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $50.05 | 2024-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $48.83 | 2025 | |
| Lundbeck LLC | $45.84 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $32.90 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $32.24 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $24.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.51 | 2024 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.27 | 2025 | Xifaxan |
| Neuronetics, INC. | $13.45 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.